Table 2 Comparison of our study results with the natural history of ONFH and outcomes of other treatments
Treatment | Number of hips | Follow-up period (years) | Collapse Rate (%) | THA -conversion rate (%) | |
|---|---|---|---|---|---|
this study | CDa + BMCb | 80 | 12 | 60% (20/33) | 34% (27/80) |
Hernigou P 2006 [21] | natural history | 121 | 14 | 77% (93/121) | 75% (91/121) |
Nam KW 2008 [22] | 105 | 8.6 | 59% (62/105) | 44% (46/105) | |
Koo KH 1995 [20] | 19 | 2 | 79% (15/19) | 68% (13/19) | |
Learmonth ID 1990 [23] | CDa | 41 | 2.6 | 83% (34/41) | – |
Gangji V 2011 [7] | 11 | 5 | 73% (8/11) | 27% (3/11) | |
Koo KH 1995 [20] | 18 | 2 | 72% (13/18) | 72% (13/18) | |
Hernigou P 2009 [6] | CDa + BMCb | 534 | 13 | 30% (160/534) | 18% (96/534) |
Hernigou P 2002 [5] | 189 | 7 | – | 18% (34/189) | |
Gangji V 2011 [7] | 13 | 5 | 23% (3/13) | – | |
Kuroda Y 2016 [18] | gelatin hydrogel + FGFc | 10 | 1 | 10% (1/10) | 0% (0/10) |
Lieberman JR 2004 [24] | CDb + fibula allograft + BMPd | 17 | 4.4 | 18% (3/17) | 18% (3/17) |
Mont A 1996 [25] | osteotomy | 77 | 11.5 | – | 24% |
Sugioka Y 1978 [26] | 41 | 2.5 | 6% (stage 1, 2) | – |